Cargando…
Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group
BACKGROUND: Dexrazoxane protects from lower-cumulative-dose doxorubicin cardiotoxicity, but the effect of dexrazoxane in children with sarcoma treated with higher-cumulative-dose doxorubicin is unknown. METHODS: We evaluated children with osteosarcoma (OS) on two Children’s Oncology Group trials wit...
Autores principales: | Kopp, Lisa M., Womer, Richard B., Schwartz, Cindy L., Ebb, David H., Franco, Vivian I., Hall, David, Barkauskas, Donald A., Krailo, Mark D., Grier, Holcombe E., Meyers, Paul A., Wexler, Leonard H., Marina, Neyssa M., Janeway, Katherine A., Gorlick, Richard, Bernstein, Mark L., Lipshultz, Steven E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048050/ https://www.ncbi.nlm.nih.gov/pubmed/32154021 http://dx.doi.org/10.1186/s40959-019-0050-9 |
Ejemplares similares
-
Dexrazoxane preferentially mitigates doxorubicin cardiotoxicity in female children with sarcoma
por: Narayan, Hari K, et al.
Publicado: (2019) -
Age, Tumor Characteristics, and Treatment Regimen as Event Predictors in Ewing: A Children's Oncology Group Report
por: Marina, Neyssa, et al.
Publicado: (2015) -
Dexrazoxane for Preventing Anthracycline Cardiotoxicity in Children with Solid Tumors
por: Choi, Hyoung Soo, et al.
Publicado: (2010) -
Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer
por: Macedo, Ariane V.S., et al.
Publicado: (2019) -
Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series
por: Ganatra, Sarju, et al.
Publicado: (2019)